EGFR and non-small cell lung carcinoma: In the IMPACT/WJOG6410l trial, patients with completely resected, EGFR-mutated, stage II to III NSCLC who received adjuvant gefitinib experienced longer disease-free survival compared to those who received chemotherapy with cisplatin and vinorelbine (35.9 vs. 25.1 months) (12); however, the difference was not statistically significant.